Certuity’s BioMarin Pharmaceuticals BMRN Stock Holding History

Certuity’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,386	Closed	-$208K	–	364
2024 Q1	$208K	Buy	+2,386	New	+$214K	0.02%	305
2023 Q4	–	Sell	-2,296	Closed	-$203K	–	352
2023 Q3	$203K	Buy	+2,296	New	+$204K	0.02%	244
2023 Q2	–	Sell	-2,603	Closed	-$253K	–	270
2023 Q1	$253K	Buy	2,603 +83	+3%	+$8.61K	0.04%	180
2022 Q4	$261K	Sell	2,520 -4,904	-66%	-$460K	0.04%	166
2022 Q3	$629K	Buy	7,424 +4,207	+131%	+$375K	0.15%	73
2022 Q2	$267K	Sell	3,217 -674	-17%	-$53.7K	0.07%	167
2022 Q1	$300K	Buy	3,891 +768	+25%	+$64.3K	0.06%	208
2021 Q4	$276K	Buy	3,123 +494	+19%	+$40.8K	0.06%	227
2021 Q3	$203K	Buy	+2,629	New	+$207K	0.04%	365
2020 Q2	–	Sell	-3,200	Closed	-$264K	–	187
2020 Q1	$264K	Hold	3,200	–	–	0.15%	115
2019 Q4	$271K	Buy	+3,200	New	+$242K	0.13%	124

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Certuity's BMRN Position: Q2 2024 in Review

Certuity sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 2,386 shares — an estimated $208K sold.

Certuity first reported a position in BMRN in Q4 2019 and held it in 11 quarters. The position peaked at $629K in Q3 2022. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Certuity reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Certuity sold 2,386 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $208K.
Certuity first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 11 quarters.
Certuity's BioMarin Pharmaceuticals position peaked at $629K in Q3 2022.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Certuity's 13F filing for Q2 2024, filed 6 Aug 2024.